Shy

Trial name or title	A Randomized, placebo‐controlled, double masked 120 subject "Futility Design" clinical trial of Ascorbic acid treatment of Charcot‐Marie‐Tooth Disease Type 1A.
Methods
Participants	CMT1A patients genetically carrying the duplication on chromosome 17q11.2 between 18‐70 years
Interventions	Ascorbic acid (Vitamin C) (4 grams/day).
Outcomes	Mean change in the CMT Neuropathy Scale following high dose ascorbic acid ingestion, assessed at baseline and every 6 months throughout the trial. (Time Frame: 25 months per subject from baseline to completion).CMT‐Neuropathy scale as primary outcome.
Starting date	April 2007
Contact information	United States, Maryland Johns Hopkins University, Dept of Neurology, Baltimore, Maryland, 21287, United States; Recruiting Lora Clawson 410‐624‐4346 lclawson@jhmi.edu Ahmet Hoke, MD, Principal Investigator United States, Michigan Wayne State University, Dept of Neurology, Detroit, Michigan, 48201, United States; Recruiting Lisa Rowe 313‐577‐1689 lrowe@med.wayne.edu Michael Shy, MD, Principal Investigator United States, New York University of Rochester Medical Center, Dept of Neurology, Rochester, New York, 14642, United States; Recruiting Patty Smith 585‐275‐0581 Patty_Smith@urmc.rochester.edu David Herrmann, MD, Principal Investigator
Notes	Listed at ClinicalTrials.gov